Definium Therapeutics (DFTX) Accumulated Expenses (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Accumulated Expenses data on file, last reported at $7.4 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $7.4 million, up 69.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 million (up 69.98% YoY), and the FY2025 annual result was $20.4 million, up 59.37% from the prior year.
• Accumulated Expenses slipped to $7.4 million in Q1 2026 per DFTX's latest filing, from $20.4 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $20.4 million in Q4 2025 and troughed at $1.6 million in Q1 2024.
• A 5-year average of $7.7 million and a median of $5.9 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2025: Accumulated Expenses tumbled 74.93% in 2023, then jumped 395.65% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $5.9 million in 2022, then surged by 97.96% to $11.6 million in 2023, then gained by 10.27% to $12.8 million in 2024, then surged by 59.37% to $20.4 million in 2025, then sank by 63.74% to $7.4 million in 2026.
• Business Quant data shows DFTX's Accumulated Expenses at $7.4 million in Q1 2026, $20.4 million in Q4 2025, and $19.0 million in Q3 2025.